Jennifer Patnaik
Concepts (431)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Visual Acuity | 31 | 2026 | 491 | 5.000 |
Why?
| | Cataract | 18 | 2024 | 212 | 3.880 |
Why?
| | Macular Degeneration | 16 | 2025 | 190 | 3.710 |
Why?
| | Geographic Atrophy | 12 | 2025 | 97 | 3.520 |
Why?
| | Phacoemulsification | 14 | 2025 | 123 | 2.540 |
Why?
| | Wet Macular Degeneration | 7 | 2025 | 58 | 2.110 |
Why?
| | Diabetic Retinopathy | 13 | 2024 | 201 | 2.060 |
Why?
| | Registries | 10 | 2025 | 2410 | 2.050 |
Why?
| | Lenses, Intraocular | 6 | 2022 | 49 | 1.830 |
Why?
| | Tomography, Optical Coherence | 11 | 2025 | 271 | 1.760 |
Why?
| | Fluorescein Angiography | 10 | 2026 | 190 | 1.700 |
Why?
| | Ophthalmology | 7 | 2026 | 119 | 1.640 |
Why?
| | Intraocular Pressure | 12 | 2026 | 326 | 1.600 |
Why?
| | Cataract Extraction | 11 | 2026 | 120 | 1.580 |
Why?
| | Optometrists | 3 | 2026 | 12 | 1.170 |
Why?
| | Glaucoma | 8 | 2025 | 247 | 1.150 |
Why?
| | Optometry | 2 | 2025 | 9 | 1.110 |
Why?
| | Retinopathy of Prematurity | 4 | 2026 | 181 | 1.100 |
Why?
| | Keratomileusis, Laser In Situ | 3 | 2024 | 20 | 1.080 |
Why?
| | Follow-Up Studies | 26 | 2026 | 5425 | 1.060 |
Why?
| | Retinal Detachment | 6 | 2023 | 73 | 0.950 |
Why?
| | Photorefractive Keratectomy | 2 | 2024 | 21 | 0.930 |
Why?
| | Fovea Centralis | 1 | 2025 | 24 | 0.920 |
Why?
| | Acanthamoeba Keratitis | 1 | 2025 | 4 | 0.920 |
Why?
| | Retrospective Studies | 57 | 2026 | 17262 | 0.920 |
Why?
| | Eye Infections, Parasitic | 1 | 2025 | 7 | 0.910 |
Why?
| | Myopia | 7 | 2024 | 59 | 0.900 |
Why?
| | Keratotomy, Radial | 2 | 2022 | 10 | 0.900 |
Why?
| | Aged, 80 and over | 29 | 2025 | 8320 | 0.890 |
Why?
| | Aged | 51 | 2026 | 26117 | 0.810 |
Why?
| | Humans | 125 | 2026 | 145482 | 0.790 |
Why?
| | Burnout, Professional | 3 | 2025 | 485 | 0.790 |
Why?
| | Refraction, Ocular | 6 | 2024 | 47 | 0.770 |
Why?
| | Capsule Opacification | 2 | 2021 | 18 | 0.730 |
Why?
| | Intraoperative Complications | 6 | 2024 | 157 | 0.710 |
Why?
| | Presbyopia | 1 | 2022 | 11 | 0.710 |
Why?
| | Surveys and Questionnaires | 15 | 2026 | 6070 | 0.700 |
Why?
| | Eye Diseases | 2 | 2020 | 95 | 0.700 |
Why?
| | Female | 78 | 2026 | 78756 | 0.700 |
Why?
| | Retinal Drusen | 4 | 2024 | 31 | 0.700 |
Why?
| | Uveitis | 4 | 2025 | 149 | 0.690 |
Why?
| | Posterior Capsulotomy | 1 | 2021 | 8 | 0.690 |
Why?
| | Posterior Capsule of the Lens | 1 | 2021 | 10 | 0.690 |
Why?
| | Trabeculectomy | 5 | 2025 | 75 | 0.680 |
Why?
| | Lasers, Solid-State | 1 | 2021 | 22 | 0.680 |
Why?
| | National Eye Institute (U.S.) | 1 | 2020 | 6 | 0.660 |
Why?
| | Male | 71 | 2026 | 72808 | 0.640 |
Why?
| | Automobile Driving | 2 | 2022 | 157 | 0.630 |
Why?
| | Colorado | 22 | 2026 | 4572 | 0.630 |
Why?
| | Glaucoma, Open-Angle | 4 | 2023 | 104 | 0.610 |
Why?
| | Retinal Neovascularization | 1 | 2019 | 28 | 0.610 |
Why?
| | Laser Therapy | 1 | 2021 | 142 | 0.600 |
Why?
| | Lens, Crystalline | 1 | 2020 | 83 | 0.590 |
Why?
| | Dementia | 1 | 2023 | 325 | 0.580 |
Why?
| | Middle Aged | 40 | 2026 | 36169 | 0.580 |
Why?
| | Vitrectomy | 6 | 2025 | 73 | 0.580 |
Why?
| | Postoperative Complications | 7 | 2026 | 2962 | 0.570 |
Why?
| | Estrogen Replacement Therapy | 1 | 2019 | 143 | 0.560 |
Why?
| | Lasers, Excimer | 3 | 2024 | 30 | 0.540 |
Why?
| | Metformin | 1 | 2021 | 324 | 0.520 |
Why?
| | Angiogenesis Inhibitors | 3 | 2026 | 238 | 0.520 |
Why?
| | Strabismus | 3 | 2023 | 71 | 0.510 |
Why?
| | Complement Activation | 5 | 2025 | 409 | 0.510 |
Why?
| | West Nile Fever | 3 | 2011 | 57 | 0.500 |
Why?
| | Internal Medicine | 1 | 2019 | 279 | 0.490 |
Why?
| | Laser Coagulation | 3 | 2026 | 79 | 0.490 |
Why?
| | Cross-Sectional Studies | 13 | 2026 | 5891 | 0.470 |
Why?
| | Refractive Errors | 3 | 2025 | 36 | 0.470 |
Why?
| | Emergency Medicine | 1 | 2019 | 282 | 0.470 |
Why?
| | Complement System Proteins | 4 | 2025 | 314 | 0.460 |
Why?
| | Choroid | 3 | 2025 | 80 | 0.460 |
Why?
| | Family Practice | 1 | 2019 | 403 | 0.460 |
Why?
| | Prevalence | 7 | 2025 | 2855 | 0.450 |
Why?
| | Self Report | 2 | 2022 | 871 | 0.440 |
Why?
| | Breast Neoplasms | 3 | 2011 | 2373 | 0.420 |
Why?
| | Vascular Endothelial Growth Factor A | 4 | 2026 | 550 | 0.420 |
Why?
| | United States | 19 | 2026 | 16114 | 0.410 |
Why?
| | Lens Implantation, Intraocular | 5 | 2022 | 80 | 0.410 |
Why?
| | Cornea | 3 | 2025 | 154 | 0.400 |
Why?
| | Biomarkers | 9 | 2025 | 4283 | 0.400 |
Why?
| | Multimodal Imaging | 2 | 2025 | 129 | 0.400 |
Why?
| | Corneal Transplantation | 2 | 2025 | 17 | 0.390 |
Why?
| | Glucocorticoids | 4 | 2026 | 531 | 0.390 |
Why?
| | Internet | 4 | 2023 | 701 | 0.390 |
Why?
| | Commerce | 2 | 2013 | 80 | 0.380 |
Why?
| | Diabetes Mellitus | 5 | 2024 | 1076 | 0.380 |
Why?
| | Vitreous Body | 4 | 2022 | 117 | 0.380 |
Why?
| | Fluocinolone Acetonide | 2 | 2023 | 15 | 0.370 |
Why?
| | Smoking Prevention | 1 | 2013 | 166 | 0.360 |
Why?
| | Tobacco Products | 1 | 2013 | 84 | 0.360 |
Why?
| | Risk Factors | 14 | 2025 | 10874 | 0.350 |
Why?
| | Ophthalmologic Surgical Procedures | 2 | 2025 | 90 | 0.350 |
Why?
| | Macula Lutea | 2 | 2023 | 21 | 0.350 |
Why?
| | Fundus Oculi | 3 | 2025 | 89 | 0.340 |
Why?
| | Disease Notification | 2 | 2011 | 16 | 0.330 |
Why?
| | Lens Capsule, Crystalline | 2 | 2021 | 10 | 0.330 |
Why?
| | Retinal Diseases | 2 | 2023 | 101 | 0.330 |
Why?
| | Telemedicine | 3 | 2026 | 960 | 0.320 |
Why?
| | Complement Factor B | 2 | 2022 | 106 | 0.310 |
Why?
| | Ophthalmologists | 2 | 2026 | 20 | 0.300 |
Why?
| | Artificial Intelligence | 2 | 2024 | 383 | 0.300 |
Why?
| | Comorbidity | 2 | 2011 | 1659 | 0.300 |
Why?
| | Eye Injuries | 2 | 2021 | 53 | 0.300 |
Why?
| | Tonometry, Ocular | 3 | 2025 | 103 | 0.300 |
Why?
| | Treatment Outcome | 12 | 2026 | 11826 | 0.290 |
Why?
| | Diabetes Mellitus, Type 2 | 4 | 2023 | 2582 | 0.280 |
Why?
| | Tertiary Care Centers | 2 | 2026 | 195 | 0.270 |
Why?
| | Infant | 13 | 2026 | 10064 | 0.270 |
Why?
| | Hepatitis A | 2 | 2011 | 25 | 0.260 |
Why?
| | Bangladesh | 3 | 2022 | 63 | 0.260 |
Why?
| | West Nile virus | 1 | 2007 | 41 | 0.260 |
Why?
| | Healthcare Disparities | 2 | 2025 | 739 | 0.250 |
Why?
| | Gestational Age | 4 | 2026 | 988 | 0.250 |
Why?
| | Time Factors | 7 | 2025 | 7171 | 0.250 |
Why?
| | Adult | 24 | 2026 | 40703 | 0.250 |
Why?
| | Health Promotion | 1 | 2013 | 775 | 0.250 |
Why?
| | Local Government | 1 | 2006 | 28 | 0.240 |
Why?
| | Pars Planitis | 1 | 2026 | 6 | 0.240 |
Why?
| | Restaurants | 1 | 2006 | 22 | 0.240 |
Why?
| | Prospective Studies | 7 | 2025 | 8039 | 0.240 |
Why?
| | Chronic Disease | 2 | 2011 | 1816 | 0.240 |
Why?
| | Vision Disorders | 3 | 2022 | 179 | 0.230 |
Why?
| | Keratoconjunctivitis | 1 | 2026 | 11 | 0.230 |
Why?
| | Blepharitis | 1 | 2026 | 9 | 0.230 |
Why?
| | Public Health Administration | 1 | 2006 | 70 | 0.230 |
Why?
| | Scleritis | 2 | 2025 | 28 | 0.230 |
Why?
| | Retinal Degeneration | 1 | 2026 | 39 | 0.230 |
Why?
| | Eye Proteins | 1 | 2026 | 85 | 0.230 |
Why?
| | Blindness | 1 | 2026 | 51 | 0.230 |
Why?
| | Mass Screening | 2 | 2024 | 1358 | 0.230 |
Why?
| | Visual Fields | 1 | 2026 | 116 | 0.230 |
Why?
| | Chemokine CCL5 | 2 | 2023 | 40 | 0.230 |
Why?
| | Dry Eye Syndromes | 1 | 2026 | 56 | 0.220 |
Why?
| | Ciliary Body | 1 | 2025 | 40 | 0.220 |
Why?
| | Pilocarpine | 1 | 2025 | 16 | 0.220 |
Why?
| | Keratoconus | 1 | 2025 | 23 | 0.220 |
Why?
| | Pemphigoid, Benign Mucous Membrane | 1 | 2024 | 6 | 0.220 |
Why?
| | Withholding Treatment | 1 | 2025 | 80 | 0.210 |
Why?
| | Occupational Stress | 1 | 2025 | 46 | 0.210 |
Why?
| | Surgery, Plastic | 1 | 2025 | 53 | 0.210 |
Why?
| | Birth Weight | 3 | 2022 | 511 | 0.210 |
Why?
| | Retinoblastoma | 1 | 2024 | 42 | 0.210 |
Why?
| | Education, Distance | 1 | 2025 | 58 | 0.210 |
Why?
| | Quality of Life | 5 | 2023 | 3195 | 0.210 |
Why?
| | Aberrometry | 2 | 2021 | 9 | 0.210 |
Why?
| | Child | 14 | 2026 | 22680 | 0.200 |
Why?
| | Optics and Photonics | 2 | 2021 | 39 | 0.200 |
Why?
| | Disease Progression | 4 | 2025 | 2862 | 0.200 |
Why?
| | Young Adult | 7 | 2026 | 14192 | 0.200 |
Why?
| | Adolescent | 12 | 2026 | 22485 | 0.200 |
Why?
| | Macular Edema | 1 | 2023 | 49 | 0.190 |
Why?
| | Postoperative Period | 5 | 2025 | 351 | 0.190 |
Why?
| | Insulins | 1 | 2023 | 38 | 0.190 |
Why?
| | Feasibility Studies | 2 | 2024 | 1119 | 0.190 |
Why?
| | Eye Burns | 1 | 2022 | 14 | 0.190 |
Why?
| | Job Satisfaction | 1 | 2025 | 237 | 0.190 |
Why?
| | Vision, Low | 1 | 2022 | 16 | 0.190 |
Why?
| | Clinical Decision-Making | 1 | 2026 | 368 | 0.190 |
Why?
| | Homosexuality, Male | 2 | 2020 | 232 | 0.190 |
Why?
| | Endoscopy | 1 | 2025 | 317 | 0.180 |
Why?
| | Outpatient Clinics, Hospital | 1 | 2023 | 80 | 0.180 |
Why?
| | Cohort Studies | 6 | 2022 | 5992 | 0.180 |
Why?
| | Eyelid Diseases | 1 | 2022 | 26 | 0.180 |
Why?
| | Compartment Syndromes | 1 | 2022 | 36 | 0.180 |
Why?
| | Odds Ratio | 4 | 2019 | 1082 | 0.180 |
Why?
| | Eyeglasses | 1 | 2022 | 24 | 0.180 |
Why?
| | Corneal Ulcer | 1 | 2022 | 20 | 0.180 |
Why?
| | Retinal Perforations | 1 | 2022 | 18 | 0.180 |
Why?
| | Incidence | 5 | 2022 | 2915 | 0.180 |
Why?
| | Clothing | 1 | 2022 | 23 | 0.180 |
Why?
| | Infant, Newborn | 6 | 2026 | 6437 | 0.170 |
Why?
| | Ocular Hypertension | 1 | 2022 | 67 | 0.170 |
Why?
| | Patient Satisfaction | 2 | 2024 | 710 | 0.170 |
Why?
| | Glycation End Products, Advanced | 1 | 2021 | 41 | 0.170 |
Why?
| | Weapons | 1 | 2021 | 9 | 0.170 |
Why?
| | Civil Disorders | 1 | 2021 | 8 | 0.170 |
Why?
| | Political Activism | 1 | 2021 | 9 | 0.170 |
Why?
| | Refractive Surgical Procedures | 1 | 2021 | 7 | 0.170 |
Why?
| | Neonatal Screening | 1 | 2022 | 179 | 0.160 |
Why?
| | Eye Banks | 1 | 2020 | 7 | 0.160 |
Why?
| | Sickness Impact Profile | 1 | 2020 | 62 | 0.160 |
Why?
| | Glaucoma Drainage Implants | 1 | 2021 | 46 | 0.160 |
Why?
| | Child, Preschool | 10 | 2026 | 11837 | 0.160 |
Why?
| | Posterior Capsular Rupture, Ocular | 1 | 2020 | 6 | 0.160 |
Why?
| | Perception | 2 | 2021 | 378 | 0.160 |
Why?
| | Accidents, Traffic | 1 | 2022 | 193 | 0.160 |
Why?
| | SEER Program | 2 | 2011 | 229 | 0.160 |
Why?
| | Health Services Accessibility | 2 | 2026 | 1101 | 0.160 |
Why?
| | Scleral Buckling | 1 | 2019 | 16 | 0.150 |
Why?
| | Retinal Hemorrhage | 1 | 2019 | 21 | 0.150 |
Why?
| | Neurodegenerative Diseases | 1 | 2022 | 150 | 0.150 |
Why?
| | Vitreoretinopathy, Proliferative | 1 | 2019 | 15 | 0.150 |
Why?
| | Legislation, Drug | 1 | 2020 | 73 | 0.150 |
Why?
| | Language | 1 | 2023 | 323 | 0.150 |
Why?
| | Hepatitis C | 1 | 2022 | 257 | 0.150 |
Why?
| | Protective Factors | 1 | 2019 | 99 | 0.150 |
Why?
| | Health Status Disparities | 1 | 2023 | 321 | 0.150 |
Why?
| | MAP Kinase Kinase 1 | 1 | 2019 | 70 | 0.150 |
Why?
| | Head Injuries, Closed | 1 | 2019 | 50 | 0.150 |
Why?
| | Oculomotor Muscles | 1 | 2020 | 86 | 0.150 |
Why?
| | Complement Membrane Attack Complex | 1 | 2019 | 38 | 0.150 |
Why?
| | Specialization | 1 | 2020 | 136 | 0.150 |
Why?
| | Complement C3a | 1 | 2019 | 40 | 0.150 |
Why?
| | Uveitis, Posterior | 1 | 2019 | 12 | 0.150 |
Why?
| | Risk Assessment | 3 | 2019 | 3759 | 0.140 |
Why?
| | Accreditation | 1 | 2019 | 101 | 0.140 |
Why?
| | Cardiovascular Diseases | 1 | 2011 | 2185 | 0.140 |
Why?
| | Choroidal Neovascularization | 1 | 2019 | 56 | 0.140 |
Why?
| | Refugees | 1 | 2020 | 83 | 0.140 |
Why?
| | Medical Marijuana | 1 | 2020 | 122 | 0.140 |
Why?
| | Case-Control Studies | 3 | 2022 | 3619 | 0.140 |
Why?
| | Down Syndrome | 1 | 2025 | 525 | 0.140 |
Why?
| | Patient Care | 1 | 2019 | 118 | 0.140 |
Why?
| | Infant, Premature | 1 | 2022 | 619 | 0.130 |
Why?
| | Glaucoma, Angle-Closure | 1 | 2018 | 23 | 0.130 |
Why?
| | Attitude of Health Personnel | 1 | 2026 | 1188 | 0.130 |
Why?
| | Health Services Needs and Demand | 1 | 2020 | 279 | 0.130 |
Why?
| | Curriculum | 1 | 2025 | 1068 | 0.130 |
Why?
| | Trabecular Meshwork | 1 | 2018 | 74 | 0.130 |
Why?
| | Proto-Oncogene Proteins B-raf | 1 | 2019 | 224 | 0.130 |
Why?
| | Sexually Transmitted Diseases | 3 | 2004 | 169 | 0.130 |
Why?
| | Practice Patterns, Physicians' | 1 | 2026 | 1369 | 0.130 |
Why?
| | Marijuana Smoking | 1 | 2020 | 249 | 0.120 |
Why?
| | Marijuana Use | 1 | 2020 | 220 | 0.120 |
Why?
| | Clinical Competence | 2 | 2025 | 1242 | 0.110 |
Why?
| | Logistic Models | 2 | 2019 | 2130 | 0.110 |
Why?
| | Disease Management | 1 | 2019 | 654 | 0.110 |
Why?
| | Population Surveillance | 2 | 2011 | 485 | 0.110 |
Why?
| | Recovery of Function | 1 | 2019 | 716 | 0.110 |
Why?
| | Aging | 1 | 2026 | 1940 | 0.110 |
Why?
| | Inflammation | 3 | 2023 | 2883 | 0.110 |
Why?
| | Proportional Hazards Models | 2 | 2024 | 1332 | 0.110 |
Why?
| | Education, Medical, Graduate | 1 | 2019 | 564 | 0.100 |
Why?
| | Disease Outbreaks | 2 | 2008 | 426 | 0.100 |
Why?
| | Retinal Pigment Epithelium | 2 | 2024 | 79 | 0.100 |
Why?
| | Condoms | 2 | 2004 | 102 | 0.100 |
Why?
| | Intravitreal Injections | 2 | 2026 | 71 | 0.100 |
Why?
| | Physicians | 1 | 2022 | 952 | 0.100 |
Why?
| | Melanoma | 1 | 2019 | 759 | 0.090 |
Why?
| | Research Design | 1 | 2019 | 1134 | 0.090 |
Why?
| | Sexual Behavior | 4 | 2004 | 496 | 0.090 |
Why?
| | Skin Neoplasms | 1 | 2019 | 850 | 0.090 |
Why?
| | Medicare | 2 | 2024 | 905 | 0.090 |
Why?
| | Axial Length, Eye | 2 | 2024 | 16 | 0.090 |
Why?
| | Hypoglycemic Agents | 1 | 2021 | 1392 | 0.090 |
Why?
| | Immunologic Factors | 2 | 2024 | 260 | 0.080 |
Why?
| | Diagnostic Errors | 1 | 2011 | 179 | 0.080 |
Why?
| | Shellfish Poisoning | 1 | 2009 | 1 | 0.080 |
Why?
| | Vibrio Infections | 1 | 2009 | 2 | 0.080 |
Why?
| | Shellfish | 1 | 2009 | 6 | 0.080 |
Why?
| | Food Industry | 1 | 2009 | 8 | 0.080 |
Why?
| | Primary Prevention | 1 | 2011 | 218 | 0.080 |
Why?
| | Food Microbiology | 1 | 2009 | 73 | 0.070 |
Why?
| | Sex Factors | 2 | 2025 | 2110 | 0.070 |
Why?
| | Cause of Death | 1 | 2011 | 469 | 0.070 |
Why?
| | Kaplan-Meier Estimate | 1 | 2011 | 974 | 0.070 |
Why?
| | Internship and Residency | 1 | 2019 | 1265 | 0.070 |
Why?
| | Mortality | 1 | 2011 | 379 | 0.070 |
Why?
| | Cryptosporidiosis | 1 | 2008 | 22 | 0.070 |
Why?
| | Academic Medical Centers | 2 | 2022 | 551 | 0.070 |
Why?
| | Antineoplastic Agents | 1 | 2019 | 2207 | 0.070 |
Why?
| | Anti-Inflammatory Agents | 2 | 2022 | 478 | 0.070 |
Why?
| | Disease Reservoirs | 1 | 2007 | 25 | 0.070 |
Why?
| | Maternal-Child Health Centers | 1 | 2007 | 8 | 0.070 |
Why?
| | Culicidae | 1 | 2007 | 33 | 0.070 |
Why?
| | Sentinel Surveillance | 1 | 2007 | 46 | 0.070 |
Why?
| | Gastroenteritis | 1 | 2008 | 63 | 0.060 |
Why?
| | Health Services Administration | 1 | 2007 | 9 | 0.060 |
Why?
| | Chickens | 1 | 2007 | 184 | 0.060 |
Why?
| | Relief Work | 1 | 2007 | 19 | 0.060 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 2 | 2019 | 839 | 0.060 |
Why?
| | Telephone | 1 | 2008 | 177 | 0.060 |
Why?
| | Birds | 1 | 2007 | 92 | 0.060 |
Why?
| | Geography | 1 | 2007 | 204 | 0.060 |
Why?
| | Health Care Surveys | 1 | 2008 | 538 | 0.060 |
Why?
| | Horses | 1 | 2007 | 227 | 0.060 |
Why?
| | Ethiopia | 1 | 2026 | 44 | 0.060 |
Why?
| | Visual Field Tests | 1 | 2026 | 32 | 0.060 |
Why?
| | Smoking | 1 | 2013 | 1468 | 0.060 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 2023 | 3917 | 0.060 |
Why?
| | Disasters | 1 | 2007 | 102 | 0.060 |
Why?
| | Environment | 1 | 2007 | 307 | 0.060 |
Why?
| | Immunoglobulins | 1 | 2006 | 162 | 0.060 |
Why?
| | Predictive Value of Tests | 1 | 2011 | 2129 | 0.060 |
Why?
| | Immunization Programs | 1 | 2007 | 193 | 0.060 |
Why?
| | Bevacizumab | 1 | 2026 | 168 | 0.060 |
Why?
| | Corneal Topography | 1 | 2025 | 25 | 0.060 |
Why?
| | Miotics | 1 | 2025 | 6 | 0.060 |
Why?
| | Muscarinic Agonists | 1 | 2025 | 14 | 0.060 |
Why?
| | Databases, Factual | 1 | 2011 | 1500 | 0.060 |
Why?
| | Azathioprine | 1 | 2025 | 44 | 0.060 |
Why?
| | Adalimumab | 1 | 2025 | 55 | 0.060 |
Why?
| | Ganglionic Stimulants | 1 | 2005 | 15 | 0.050 |
Why?
| | Tomography | 1 | 2025 | 45 | 0.050 |
Why?
| | Lubricant Eye Drops | 1 | 2024 | 9 | 0.050 |
Why?
| | Ontario | 1 | 2024 | 96 | 0.050 |
Why?
| | Infliximab | 1 | 2025 | 111 | 0.050 |
Why?
| | Benchmarking | 1 | 2026 | 190 | 0.050 |
Why?
| | Mycophenolic Acid | 1 | 2025 | 120 | 0.050 |
Why?
| | Retinal Neoplasms | 1 | 2024 | 37 | 0.050 |
Why?
| | Conjunctivitis | 1 | 2024 | 30 | 0.050 |
Why?
| | Rwanda | 1 | 2024 | 35 | 0.050 |
Why?
| | Ophthalmic Solutions | 1 | 2024 | 80 | 0.050 |
Why?
| | Needs Assessment | 1 | 2007 | 401 | 0.050 |
Why?
| | Attitude to Health | 1 | 2007 | 431 | 0.050 |
Why?
| | Capacity Building | 1 | 2024 | 62 | 0.050 |
Why?
| | Patient Discharge | 1 | 2011 | 992 | 0.050 |
Why?
| | Methotrexate | 1 | 2025 | 232 | 0.050 |
Why?
| | Vision Tests | 1 | 2023 | 22 | 0.050 |
Why?
| | Hospitals, County | 1 | 2023 | 11 | 0.050 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 1 | 2011 | 919 | 0.050 |
Why?
| | Observational Studies as Topic | 1 | 2023 | 133 | 0.050 |
Why?
| | Health Surveys | 2 | 2021 | 518 | 0.050 |
Why?
| | Postoperative Care | 1 | 2025 | 286 | 0.050 |
Why?
| | Tobacco Use Disorder | 1 | 2005 | 218 | 0.050 |
Why?
| | Interleukin-4 | 1 | 2023 | 208 | 0.050 |
Why?
| | Complement Factor I | 1 | 2022 | 12 | 0.050 |
Why?
| | Gonorrhea | 1 | 2003 | 63 | 0.050 |
Why?
| | Electronic Health Records | 1 | 2011 | 1186 | 0.050 |
Why?
| | Mentors | 1 | 2024 | 218 | 0.050 |
Why?
| | Aqueous Humor | 1 | 2022 | 38 | 0.050 |
Why?
| | Orbit | 1 | 2022 | 66 | 0.050 |
Why?
| | Phenotype | 2 | 2022 | 3157 | 0.040 |
Why?
| | Global Health | 1 | 2025 | 404 | 0.040 |
Why?
| | Hospitals, Pediatric | 1 | 2026 | 557 | 0.040 |
Why?
| | Cluster Analysis | 1 | 2023 | 517 | 0.040 |
Why?
| | Drug Implants | 1 | 2022 | 83 | 0.040 |
Why?
| | Alanine Transaminase | 1 | 2022 | 151 | 0.040 |
Why?
| | Nicotine | 1 | 2005 | 334 | 0.040 |
Why?
| | Reference Standards | 1 | 2022 | 178 | 0.040 |
Why?
| | Capsulorhexis | 1 | 2021 | 8 | 0.040 |
Why?
| | Albumins | 1 | 2022 | 119 | 0.040 |
Why?
| | Communication Barriers | 1 | 2023 | 130 | 0.040 |
Why?
| | Safety-net Providers | 1 | 2023 | 129 | 0.040 |
Why?
| | Morbidity | 1 | 2022 | 322 | 0.040 |
Why?
| | Dissent and Disputes | 1 | 2021 | 18 | 0.040 |
Why?
| | Retinal Ganglion Cells | 1 | 2022 | 117 | 0.040 |
Why?
| | Fibrinogen | 1 | 2022 | 181 | 0.040 |
Why?
| | Hepacivirus | 1 | 2022 | 244 | 0.040 |
Why?
| | Intraoperative Period | 1 | 2020 | 69 | 0.040 |
Why?
| | Smoking Cessation | 1 | 2005 | 437 | 0.040 |
Why?
| | Crowding | 1 | 2021 | 37 | 0.040 |
Why?
| | Biometry | 1 | 2021 | 66 | 0.040 |
Why?
| | Risk-Taking | 1 | 2003 | 325 | 0.040 |
Why?
| | Myanmar | 1 | 2020 | 7 | 0.040 |
Why?
| | Myotomy | 1 | 2020 | 15 | 0.040 |
Why?
| | Rupture | 1 | 2020 | 91 | 0.040 |
Why?
| | Immunosuppressive Agents | 1 | 2025 | 842 | 0.040 |
Why?
| | Vision, Binocular | 1 | 2020 | 47 | 0.040 |
Why?
| | Adrenal Cortex Hormones | 1 | 2023 | 482 | 0.040 |
Why?
| | Eye Movements | 1 | 2020 | 94 | 0.040 |
Why?
| | Health Education | 1 | 2003 | 345 | 0.040 |
Why?
| | Survival Rate | 1 | 2024 | 2092 | 0.040 |
Why?
| | Chromatography, Liquid | 1 | 2021 | 445 | 0.040 |
Why?
| | HIV | 1 | 2020 | 252 | 0.040 |
Why?
| | Canada | 1 | 2020 | 434 | 0.040 |
Why?
| | C-Reactive Protein | 1 | 2021 | 422 | 0.040 |
Why?
| | Remission, Spontaneous | 1 | 2019 | 39 | 0.040 |
Why?
| | Microscopy, Acoustic | 1 | 2018 | 10 | 0.040 |
Why?
| | Attitude | 1 | 2021 | 260 | 0.040 |
Why?
| | Pilot Projects | 1 | 2024 | 1896 | 0.040 |
Why?
| | Ophthalmoscopy | 1 | 2018 | 38 | 0.040 |
Why?
| | Pyrimidinones | 1 | 2019 | 125 | 0.040 |
Why?
| | Preoperative Period | 1 | 2019 | 149 | 0.040 |
Why?
| | Exfoliation Syndrome | 1 | 2018 | 10 | 0.030 |
Why?
| | Corneal Pachymetry | 1 | 2018 | 16 | 0.030 |
Why?
| | Clinical Trials as Topic | 1 | 2023 | 1058 | 0.030 |
Why?
| | Circadian Rhythm | 1 | 2023 | 512 | 0.030 |
Why?
| | Pseudophakia | 1 | 2018 | 21 | 0.030 |
Why?
| | Tandem Mass Spectrometry | 1 | 2021 | 566 | 0.030 |
Why?
| | Ambulatory Care | 1 | 2023 | 608 | 0.030 |
Why?
| | Severity of Illness Index | 1 | 2026 | 2945 | 0.030 |
Why?
| | Disease-Free Survival | 1 | 2019 | 771 | 0.030 |
Why?
| | Prosthesis Design | 1 | 2020 | 360 | 0.030 |
Why?
| | Physical Examination | 1 | 2019 | 243 | 0.030 |
Why?
| | Cost-Benefit Analysis | 1 | 2020 | 645 | 0.030 |
Why?
| | Longitudinal Studies | 1 | 2025 | 2950 | 0.030 |
Why?
| | Ambulatory Care Facilities | 3 | 2004 | 269 | 0.030 |
Why?
| | Delivery of Health Care | 1 | 2024 | 948 | 0.030 |
Why?
| | Stents | 1 | 2021 | 570 | 0.030 |
Why?
| | Equipment Design | 1 | 2018 | 532 | 0.030 |
Why?
| | Sex Characteristics | 1 | 2022 | 779 | 0.030 |
Why?
| | Referral and Consultation | 1 | 2022 | 862 | 0.030 |
Why?
| | Mental Health | 1 | 2022 | 795 | 0.030 |
Why?
| | Sleep | 1 | 2023 | 891 | 0.030 |
Why?
| | Reproducibility of Results | 1 | 2023 | 3424 | 0.030 |
Why?
| | Multivariate Analysis | 1 | 2019 | 1544 | 0.030 |
Why?
| | Program Evaluation | 2 | 2011 | 945 | 0.030 |
Why?
| | Anxiety | 1 | 2022 | 1127 | 0.030 |
Why?
| | Proteins | 1 | 2020 | 1020 | 0.030 |
Why?
| | Child Abuse | 1 | 2019 | 552 | 0.020 |
Why?
| | Anti-Bacterial Agents | 1 | 2024 | 1953 | 0.020 |
Why?
| | Proteomics | 1 | 2020 | 1191 | 0.020 |
Why?
| | T-Lymphocytes | 1 | 2022 | 1996 | 0.020 |
Why?
| | Protein Kinase Inhibitors | 1 | 2019 | 979 | 0.020 |
Why?
| | Depression | 1 | 2022 | 1573 | 0.020 |
Why?
| | Pandemics | 1 | 2021 | 1706 | 0.020 |
Why?
| | Animals | 3 | 2009 | 38141 | 0.020 |
Why?
| | Legionellosis | 1 | 2011 | 2 | 0.020 |
Why?
| | Blood Glucose | 1 | 2021 | 2330 | 0.020 |
Why?
| | Prognosis | 1 | 2019 | 4321 | 0.020 |
Why?
| | Medical Audit | 1 | 2011 | 77 | 0.020 |
Why?
| | Whooping Cough | 1 | 2011 | 55 | 0.020 |
Why?
| | Haemophilus Infections | 1 | 2011 | 45 | 0.020 |
Why?
| | Hospitals, Urban | 1 | 2011 | 143 | 0.020 |
Why?
| | International Classification of Diseases | 1 | 2011 | 148 | 0.020 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2019 | 1963 | 0.020 |
Why?
| | Cryptosporidium | 1 | 2008 | 15 | 0.020 |
Why?
| | Caliciviridae Infections | 1 | 2008 | 18 | 0.020 |
Why?
| | Norovirus | 1 | 2008 | 22 | 0.020 |
Why?
| | Aid to Families with Dependent Children | 1 | 2007 | 3 | 0.020 |
Why?
| | Residence Characteristics | 1 | 2011 | 376 | 0.020 |
Why?
| | Diphtheria-Tetanus-acellular Pertussis Vaccines | 1 | 2007 | 91 | 0.020 |
Why?
| | Faculty | 1 | 2008 | 153 | 0.020 |
Why?
| | Medically Uninsured | 1 | 2007 | 132 | 0.020 |
Why?
| | Family Characteristics | 1 | 2008 | 198 | 0.020 |
Why?
| | Sensitivity and Specificity | 1 | 2011 | 2002 | 0.010 |
Why?
| | Pharmaceutical Preparations | 1 | 2007 | 170 | 0.010 |
Why?
| | Guideline Adherence | 1 | 2009 | 590 | 0.010 |
Why?
| | Maryland | 1 | 2005 | 67 | 0.010 |
Why?
| | Administration, Topical | 1 | 2005 | 153 | 0.010 |
Why?
| | Urban Health Services | 1 | 2004 | 71 | 0.010 |
Why?
| | Acute Disease | 1 | 2007 | 1040 | 0.010 |
Why?
| | Office Visits | 1 | 2003 | 92 | 0.010 |
Why?
| | Syphilis | 1 | 2003 | 38 | 0.010 |
Why?
| | Administration, Oral | 1 | 2005 | 863 | 0.010 |
Why?
| | Antiretroviral Therapy, Highly Active | 1 | 2003 | 279 | 0.010 |
Why?
| | Risk | 1 | 2004 | 917 | 0.010 |
Why?
| | Mothers | 1 | 2007 | 767 | 0.010 |
Why?
| | Urban Population | 1 | 2004 | 494 | 0.010 |
Why?
| | HIV Infections | 1 | 2003 | 3189 | 0.000 |
Why?
|
|
Patnaik's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|